Madrigal Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences
June 01 2023 - 8:00AM
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage
biopharmaceutical company pursuing novel therapeutics for
nonalcoholic steatohepatitis (NASH), announced today its management
team will participate in fireside chats at two upcoming investor
conferences:
Jefferies Healthcare Conference2:30 pm ET on
Wednesday, June 7, 2023.
Goldman Sachs Global Healthcare Conference
12:20 pm ET on Tuesday, June 13, 2023.
The fireside chats will be webcast and archived recordings will
be available for replay in the Investors section of the Madrigal
website after the events.
About Madrigal PharmaceuticalsMadrigal
Pharmaceuticals, Inc. (Nasdaq: MDGL) is a clinical-stage
biopharmaceutical company pursuing novel therapeutics for
nonalcoholic steatohepatitis (NASH), a liver disease with high
unmet medical need. Madrigal’s lead candidate, resmetirom, is a
once daily, oral, thyroid hormone receptor (THR)-β selective
agonist designed to target key underlying causes of NASH in the
liver. For more information, visit www.madrigalpharma.com.
Investor Contact Alex Howarth, Madrigal
Pharmaceuticals, Inc., IR@madrigalpharma.com
Media ContactChristopher Frates, Madrigal
Pharmaceuticals, Inc., media@madrigalpharma.com
Madrigal Pharmaceuticals (NASDAQ:MDGL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Madrigal Pharmaceuticals (NASDAQ:MDGL)
Historical Stock Chart
From Apr 2023 to Apr 2024